Business Wire

TRM Labs Acquires UK Crypto Investigations Training Company CSITech

Share

Today, TRM Labs, the blockchain intelligence company, announced the acquisition of CSITech, a global leader in crypto and blockchain investigative training. CSITech adds its nearly two decades of investigative training experience to TRM’s suite of compliance tools and service offerings for crypto business, government and law enforcement agency, and financial institution clientele.

CSITech, a UK-based firm, delivers in-person and online training on blockchain and cryptocurrency investigations. CSITech is widely recognized as the leading crypto investigations training firm and has trained international law enforcement bodies at all levels on investigative techniques and best practices for investigating cryptocurrency-related crimes.

“TRM is on a mission to bring trust and safety to the crypto economy. Providing first-rate tools and training to law enforcement and compliance professionals that help safeguard this ecosystem is a core component,” said Esteban Castaño, co-founder and CEO of TRM Labs. “We’re excited about the expanded training capabilities Nick and his team of experts will allow us to offer to our global base of customers.”

CSITech’s expertise will augment and expand TRM’s existing portfolio of training services, which includes TRM Academy – an extensive library of self-serve digital courses available to all TRM customers as a complimentary resource – and several multi-day certification courses designed to advance the skills of professionals ranging compliance practitioners who are new to crypto to experienced crypto investigators.

“We’re committed to delivering the best training and certifications to our students, clients and partners in pursuit of our tireless mission to see the crypto space become a safer and more trustworthy environment for all,” said Nick Furneaux, Managing Director at CSITech.

“The pro level courses we are delivering are for those with a high existing knowledge base, who have taken a number of existing courses available and are looking to acquire the techniques and skills to take their capabilities, services offerings and careers to the next level.”

Mr. Furneaux is an internationally renowned expert of blockchain forensics and author of Investigating Cryptocurrencies: Understanding, Extracting, and Analyzing Blockchain Evidence (2018). In 18 years of operation, CSITech established itself as the preeminent crypto investigations training provider with top law enforcement agents among its alumni. Former pupils are currently leading some of the most well known cryptocurrency investigations in the sector, including cases involving hacks against exchanges, organized crime groups and sanctions evasion.

“Since 2019, TRM Labs has constantly innovated to build a blockchain investigations tool for today’s crypto ecosystem. We at CSITech are thrilled to join TRM on its mission to build a safer financial system for billions of people and expand our capability to train the next generation of leading cryptocurrency investigators,” said Furneaux. He and other CSITech personnel join TRM’s Training and Certifications team, operating in close collaboration with TRM’s Global Investigations team led by former IRS-Criminal Investigations (IRS-CI) Special Agent Chris Janczewski, who joined TRM in March 2022.

“The cryptocurrency space is evolving at tremendous pace and requires investigators and industry leaders to educate and prepare to match the industry’s scale,” said Chris Janczewski, Head of Global Investigations for TRM. “My team and I work closely with TRM’s Training and Certifications program to ensure that the course material continues to reflect the reality of the job on the ground.”

TRM’s certifications portfolio includes a range of multi-day course offerings that can be delivered virtually or in-person: TRM Crypto Fundamentals Certification (TRM-CFC), TRM Certified Crypto Compliance Specialist (TRM-CCS), TRM Certified Investigator (TRM-CI) and TRM Advanced Crypto Investigator (TRM-ACI). For more information and to enquire about booking group or individual courses, visit the TRM website here.

About TRM Labs

TRM provides blockchain intelligence to help financial institutions, cryptocurrency businesses and public agencies detect, investigate and manage crypto-related fraud and financial crime. TRM's risk management platform includes solutions for cryptocurrency anti-money laundering (AML), transaction monitoring and wallet screening, entity risk scoring including Know-Your-VASP, and transaction tracing for investigations. These tools enable a rapidly growing cohort of organizations around the world to safely embrace cryptocurrency-related transactions, products, and partnerships. TRM is based in San Francisco, CA and is hiring across engineering, product, sales, and data science. To learn more, visit www.trmlabs.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Rachel Saulpaugh
trm-labs@wachsman.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye